Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transfusion of blood products Clear all
Terminated Not applicable Interventional

Impact of Intraoperative Cell Salvage

NCT06240117
View directory record Official record
Conditions
Peripartum Anemia
Interventions
Intraoperative cellular salvage
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 4, 2026, 6:52 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Tranexamic Acid in Adherent Placenta (TAP)

NCT02329756
View directory record Official record
Conditions
Placenta Accreta
Interventions
Tranexamic Acid (TXA), Sodium Chloride 0.9%
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Results available

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

NCT04704869
View directory record Official record
Conditions
Trauma Injury
Interventions
Cryoprecipitate, Red Blood Cells, Plasma, Platelets, Whole Blood
Biological
Lead sponsor
Bryan Cotton
Other
Eligibility
16 Years and older
Enrollment
1,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 4, 2026, 6:52 AM EDT
Withdrawn Not applicable Interventional

Blood Conservation in Cardiac Surgery

NCT01463345
View directory record Official record
Conditions
Transfusion Reactions, Post Cardiac Surgery
Interventions
Blood transfusion
Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 4, 2026, 6:52 AM EDT
Active, not recruiting Phase 1 Interventional

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380
View directory record Official record
Conditions
Renal Failure
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair

NCT02483702
View directory record Official record
Conditions
Graft Versus Host Disease, Hyperkalemia, Craniectomy, Synostectomy, FOA, Congenital Malformations
Interventions
Irradiated Blood Transfusions, Non-Irradiated Blood Transfusions
Other
Lead sponsor
Valley Anesthesiology Consultants
Other
Eligibility
2 Months to 6 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 4, 2026, 6:52 AM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

NCT00281879
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions
anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock

NCT01611935
View directory record Official record
Conditions
Traumatic Shock
Interventions
Vasopressin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional Results available

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

NCT01730118
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu Expression
Interventions
Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 4, 2026, 6:52 AM EDT
Completed No phase listed Observational

Trauma Induced Coagulopathy and Inflammation

NCT03128658
View directory record Official record
Conditions
Trauma Injury, Trauma, Coagulopathy
Interventions
Thromboelastography, Computational model
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Results available

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

NCT01035229
View directory record Official record
Conditions
Carcinoma
Interventions
Everolimus, Everolimus Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 4, 2026, 6:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

NCT01306019
View directory record Official record
Conditions
X-linked Severe Combined Immunodeficiency (XSCID)
Interventions
Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector, Busulfan, Palifermin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

NCT03096782
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
Interventions
Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Biological · Drug · Radiation + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 4, 2026, 6:52 AM EDT
Recruiting Not applicable Interventional

Effect of Giving Reduced Fluid in Children After Trauma

NCT04201704
View directory record Official record
Conditions
Critical Illness, Pediatrics, General Surgery, Fluid Therapy, Wounds and Injuries
Interventions
Balanced crystalloid solution volume administration, Packed Erythrocytes Units, Blood Product Unit volume, Plasma volume, Platelets volume
Other
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 15 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Buffalo, New York • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Not applicable Interventional

Use of Cell Salvage Post-operatively in Infants to Decrease Use of Allogeneic Blood Product Transfusions

NCT01211366
View directory record Official record
Conditions
Transfusion
Interventions
Cell Saver RBCs, Conventional volume infusion
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 4, 2026, 6:52 AM EDT
Completed No phase listed Observational

TT-CMV Observational Birth Cohort Study

NCT00907686
View directory record Official record
Conditions
Cytomegalovirus Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
1 Hour to 5 Days
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Duration of Red Blood Cell Storage Prior to Transfusion

NCT02087514
View directory record Official record
Conditions
Iron, Blood Level Abnormal
Interventions
Blood Transfusion, Packed red blood cells
Procedure · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 4, 2026, 6:52 AM EDT
Active, not recruiting Not applicable Interventional

Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

NCT04922307
View directory record Official record
Conditions
Kidney Cancer
Interventions
Blood Sparing Protocol, Standard Blood Replacement
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

FEIBA and Use of Blood Products in Cardiac Surgery

NCT02577614
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
FEIBA, Normal Saline
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 4, 2026, 6:52 AM EDT
Completed No phase listed Observational

Use of the Quantra QPlus Sytem in Cardiac Surgery

NCT05501730
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Quantra QPlus System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Prescott, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 4, 2026, 6:52 AM EDT
Not listed Not applicable Interventional

Neonatal Brain Oxygenation Study

NCT04439968
View directory record Official record
Conditions
Cerebral Hypoxia
Interventions
Clinical algorithm
Other
Lead sponsor
Stanford University
Other
Eligibility
Up to 2 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

Amicar Pharmacokinetics of Children Having Craniofacial Surgery

NCT00912119
View directory record Official record
Conditions
Craniosynostosis
Interventions
Epsilon-Aminocaproic Acid
Drug
Lead sponsor
Paul Stricker
Other
Eligibility
2 Months to 24 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 4, 2026, 6:52 AM EDT
Terminated Phase 2 Interventional Results available

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

NCT02029638
View directory record Official record
Conditions
Kidney Transplantation
Interventions
anti-thymocyte globulin, Fludarabine, Cyclophosphamide, Total Body Irradiation, acetaminophen, diphenhydramine, methylprednisolone, bone marrow transplant, MESNA, mycophenolate mofetil, prednisone, filgrastim
Biological · Drug · Radiation
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 4 Interventional Results available

Early Whole Blood in Patients Requiring Transfusion After Major Trauma

NCT01227005
View directory record Official record
Conditions
Trauma/Injury Problem
Interventions
Transfusion of blood products
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 4, 2026, 6:52 AM EDT